AMNEAL PHARMACEUTICALS INC (AMRX) Fundamental Analysis & Valuation
NASDAQ:AMRX • US03168L1052
Current stock price
This AMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AMRX Profitability Analysis
1.1 Basic Checks
- In the past year AMRX was profitable.
- AMRX had a positive operating cash flow in the past year.
- In multiple years AMRX reported negative net income over the last 5 years.
- Each year in the past 5 years AMRX had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.96%, AMRX belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
- AMRX has a Return On Invested Capital of 11.24%. This is amongst the best in the industry. AMRX outperforms 90.58% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AMRX is below the industry average of 13.10%.
- The 3 year average ROIC (10.04%) for AMRX is below the current ROIC(11.24%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.96% | ||
| ROE | N/A | ||
| ROIC | 11.24% |
1.3 Margins
- With an excellent Profit Margin value of 2.39%, AMRX belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
- AMRX's Profit Margin has declined in the last couple of years.
- The Operating Margin of AMRX (13.18%) is better than 85.34% of its industry peers.
- In the last couple of years the Operating Margin of AMRX has grown nicely.
- AMRX has a Gross Margin (36.88%) which is in line with its industry peers.
- AMRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.18% | ||
| PM (TTM) | 2.39% | ||
| GM | 36.88% |
2. AMRX Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
- Compared to 1 year ago, AMRX has more shares outstanding
- The number of shares outstanding for AMRX has been increased compared to 5 years ago.
- The debt/assets ratio for AMRX has been reduced compared to a year ago.
2.2 Solvency
- AMRX has an Altman-Z score of 1.98. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- AMRX has a Altman-Z score of 1.98. This is comparable to the rest of the industry: AMRX outperforms 59.69% of its industry peers.
- AMRX has a debt to FCF ratio of 11.66. This is a negative value and a sign of low solvency as AMRX would need 11.66 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 11.66, AMRX is doing good in the industry, outperforming 78.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.66 | ||
| Altman-Z | 1.98 |
2.3 Liquidity
- AMRX has a Current Ratio of 2.17. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
- AMRX has a Current ratio (2.17) which is comparable to the rest of the industry.
- A Quick Ratio of 1.48 indicates that AMRX should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.48, AMRX is not doing good in the industry: 67.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.48 |
3. AMRX Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 44.83% over the past year.
- Measured over the past 5 years, AMRX shows a small growth in Earnings Per Share. The EPS has been growing by 5.92% on average per year.
- The Revenue has grown by 8.05% in the past year. This is quite good.
- The Revenue has been growing by 8.66% on average over the past years. This is quite good.
3.2 Future
- AMRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.77% yearly.
- Based on estimates for the next years, AMRX will show a decrease in Revenue. The Revenue will decrease by -0.47% on average per year.
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. AMRX Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 15.39, which indicates a correct valuation of AMRX.
- Compared to the rest of the industry, the Price/Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 86.39% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.38. AMRX is valued slightly cheaper when compared to this.
- AMRX is valuated correctly with a Price/Forward Earnings ratio of 12.80.
- Based on the Price/Forward Earnings ratio, AMRX is valued cheaper than 83.77% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of AMRX to the average of the S&P500 Index (38.20), we can say AMRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.39 | ||
| Fwd PE | 12.8 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 87.43% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 85.34% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.28 | ||
| EV/EBITDA | 10.48 |
4.3 Compensation for Growth
- AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of AMRX may justify a higher PE ratio.
- AMRX's earnings are expected to grow with 18.59% in the coming years. This may justify a more expensive valuation.
5. AMRX Dividend Analysis
5.1 Amount
- No dividends for AMRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AMRX Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:AMRX (4/16/2026, 10:16:09 AM)
12.93
-0.12 (-0.92%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.39 | ||
| Fwd PE | 12.8 | ||
| P/S | 1.37 | ||
| P/FCF | 18.28 | ||
| P/OCF | 12.13 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.48 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.96% | ||
| ROE | N/A | ||
| ROCE | 14.23% | ||
| ROIC | 11.24% | ||
| ROICexc | 12.5% | ||
| ROICexgc | 23.19% | ||
| OM | 13.18% | ||
| PM (TTM) | 2.39% | ||
| GM | 36.88% | ||
| FCFM | 7.47% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.66 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 51.15% | ||
| Cap/Sales | 3.79% | ||
| Interest Coverage | 2.01 | ||
| Cash Conversion | 54.71% | ||
| Profit Quality | 313.13% | ||
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | 1.98 |
AMNEAL PHARMACEUTICALS INC / AMRX Fundamental Analysis FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status for AMRX stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
Can you provide the profitability details for AMNEAL PHARMACEUTICALS INC?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for AMRX stock?
The Price/Earnings (PE) ratio for AMNEAL PHARMACEUTICALS INC (AMRX) is 15.39 and the Price/Book (PB) ratio is -58.26.
Can you provide the expected EPS growth for AMRX stock?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 20.21% in the next year.